LANGE LOUIS G 4

What Happened

• Director Louis G. Lange reported open-market sales of NewAmsterdam Pharma (NAMS) common stock on March 11, 2026.
• He disposed of 44,173 shares at a weighted average price of $30.41 (proceeds $1,343,301) and 446 shares at a weighted average price of $31.23 (proceeds $13,929), for total proceeds of approximately $1,357,230.
• These were sales (not purchases or option exercises), which are often routine insider liquidity events and do not by themselves indicate company performance.

Key Details

• Transaction date: March 11, 2026; Form 4 filed March 12, 2026 (timely filing).
• Reported weighted-average prices reflect multiple trades: 44,173 shares sold at $30.11–$31.08 (F1) and 446 shares sold at $31.13–$31.31 (F2). The filing offers to provide per-trade breakdowns on request.
• Shares owned after the transactions are not specified in the summary data provided.
• Transaction code: S (sale). No 10b5-1 plan, tax-withholding, gift, or option-exercise language was reported in the provided details.

Context

• Sales by insiders can be routine (diversification, tax planning) and do not necessarily signal a change in company prospects; purchases generally carry more informational weight.
• This filing documents open-market disposals by a director; there is no indication here that these were part of an option exercise or a gift.